including airway remodelling in asthma, with mitigation of the subsequent development of fibrosis 22, 23 . Metformin was recently shown to prevent lung fibrosis via NADPH oxidase 4 (NOX4) suppression 24 . Interestingly, AMPK activation may inhibit myofibroblast differentiation by TGF-β 1, supporting a preventive role of AMPK in the development of fibrosis 25, 26 ; however, whether modulation of this pathway is beneficial in established fibrosis is not known.
Lungs from human subjects with IPF are characterized by architectural tissue remodelling with accumulation of α -smooth muscle actin (α -SMA)-expressing myofibroblasts within fibroblastic foci (Fig. 1a,b and Supplementary Fig. 1a,b ). Within these regions of active fibrosis, a significant decrease in AMPK activity, as evidenced by reduced Thr172 AMPK phosphorylation, is observed ( Fig. 1a-c and Supplementary Fig. 1c-e ). While α -SMA-expressing myofibroblasts are largely deficient in AMPK activity, alveolar epithelial cells (AECs) display relatively high levels of AMPK activity in both control and IPF lung tissues (Fig. 1a -c and Supplemental Fig. 2 ). Next, we examined the state of AMPK activity in isolated lung fibroblasts from human subjects with IPF and age-matched control subjects (Supplementary Tables 1 and 2 ). Despite notable heterogeneity, IPF fibroblasts demonstrate lower levels of AMPK activity ( Supplementary Fig. 3a ), in association with mTOR (mammalian target of rapamicin) activation (evidenced by ribosomal protein S6 phosphorylation), hypoxia-inducible factor 1 alpha (HIF-1α ) accumulation, diminished autophagy (evidenced by LC3BI to LC3BII conversion) and increased lactate production ( Supplementary  Fig. 3b ). The AMP mimetic 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) activates AMPK in a dose-dependent manner, reduces mTOR-dependent S6 phosphorylation, and induces autophagy, in association with reduced constitutive levels of the extracellular matrix (ECM) proteins, collagen and fibronectin ( Fig. 1d,e ). Together, these studies indicate that AMPK activation reprograms metabolism in IPF fibroblasts by enhancing autophagy and reducing mTOR activation, while downregulating steady-state levels of ECM proteins.
TGF-β 1 is critical mediator of fibrogenic processes in diverse organ systems, including IPF 8 . Previous studies have reported anti-fibrotic effects of metformin in multiple organs, primarily by interfering with TGF-β 1 signalling 22, [26] [27] [28] [29] . However, whether AMPK activation is capable of deactivating differentiated myofibroblasts and resolving fibrosis is not known. We confirmed that the AMPK activator AICAR prevents collagen type I, fibronectin and α -SMA expression in fibroblasts stimulated with TGF-β 1 (Supplementary Letters NATure MedICINe Fig. 3c,d) . In contrast, silencing of AMPK mediates a marked increase in constitutive and TGF-β 1-induced expression of fibronectin ( Supplementary Fig. 3e ). To determine the effects of AMPK activation on differentiated myofibroblasts, cells were treated with AICAR (250 µ M) or metformin (500 µ M) for 24 h after TGF-β 1 (2.5 ng ml −1 ) stimulation; this resulted in a significant decrease (control), n = 9 (IPF) for both pT172-AMPK and α -SMA; n = 8 (control), n = 6 (IPF) for T1α . *P < 0.05 (Student's t-test). d, Representative western blots and quantitative analysis showing the amounts of pT172-AMPK, pS240/244-S6 kinase, collagen type I, fibronectin, LC3BI/II and β -actin in IPF fibroblasts stimulated with AICAR (24 h). The LC3II/I ratio was obtained from cells treated with AICAR and chloroquine. Data presented as mean ± s.d., n = 3 or n = 4. *P < 0.05 (analysis of variance, ANOVA).
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in the steady-state levels of collagen and fibronectin ( Fig. 2a,b ). Next, we examined if the AMPK-dependent activation of autophagy regulates ECM turnover. The addition of chloroquine, which blocks late autophagy, shows intracellular accumulation of collagen within stabilized autophagosomes ( Fig. 2c,d ). This suggested the possibility that autophagy controls the turnover of collagen. To test this, we silenced upstream regulators of autophagy, including AMPK, beclin or LC3B. The effects of AICAR on suppressing steady-state levels of collagen induced by TGF-β 1 is lost when autophagy is inhibited ( Fig. 2e,f) . Notably, prolonged activation of AMPK by AICAR reduces the accumulation of collagen within the extracellular space ( Supplementary Fig. 3f ). Loss of AMPK activity may contribute to mitochondrial dysfunction and the metabolic reprogramming that regulates myofibroblast differentiation and function 10, 11, 30 . Transmission electron microscope (TEM) analysis indicated that IPF myofibroblasts contain fragmented mitochondria, probably due to defective clearance of damaged/dysfunctional mitochondria ( Fig. 3a ). This is accompanied by enhanced mitochondrial reactive oxygen species formation (data not shown). Bioenergetic analysis of 
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AMPK-deficient fibroblasts shows diminished basal oxygen consumption, adenosine triphosphate (ATP)-linked O 2 consumption rate (OCR), maximal respiration and mitochondrial reserve capacity ( Fig. 3b ). S555-ULK1 phosphorylation 31 , a key regulator of mitophagy, was also diminished in AMPK −/− fibroblasts ( Fig. 3c ). Mitochondria are critical regulators and effectors of programmed cell death 32, 33 , and metabolic reprogramming towards aerobic glycolysis has been implicated in cellular resistance to apoptosis in 
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NATure MedICINe cancer cells 34, 35 . Mechanism(s) of acquired apoptosis resistance in IPF myofibroblasts is not well understood. However, TGF-β 1 has been shown to inhibit serum deprivation-induced apoptosis in lung myofibroblasts 36 . Here, we have found that AMPK activation is capable of reversing apoptosis resistance in differentiated myofibroblasts ( Fig. 3d,e ). Additionally, AMPK activation sensitizes TGF-β 1-differentiated myofibroblasts to intrinsic apoptosis, in particular induced by antimycin A, a mitochondrial inhibitor of electron transport chain (ETC) complex III (Fig. 3f ). This enhanced sensitivity to apoptosis is lost in AMPK-silenced fibroblasts (Supplemental Fig. 3g ). A possible mechanism by which fibroblasts recover sensitivity to intrinsic apoptosis may be due to enhanced mitochondrial biogenesis. We examined if AMPK activation can promote mitochondrial biogenesis in IPF fibroblasts. The AMPK activators, AICAR or metformin, upregulate mitochondrial transcription factor-A (TFAM, a master regulator of mitochondrial biogenesis) and induce expression of the major components of mitochondrial ETC complexes (Fig. 3g) . These results suggest that, in addition to regulating ECM homeostasis, AMPK activation upregulates mitochondrial biogenesis and restores myofibroblast sensitivity to intrinsic apoptosis.
The mouse model of bleomycin-induced lung injury, although the most widely utilized for the study of lung fibrosis, is known to resolve over time 15 ; however, the mechanisms promoting resolution are not well understood. Metformin is a safe and widely used agent for non-insulin-dependent diabetes, and has therapeutic potential to restore glucose and lipid metabolic homeostasis 37, 38 . We explored whether metformin, via AMPK activation, can accelerate the resolution of fibrosis in the bleomycin lung fibrosis model. Initial results showed that a single or two doses of metformin (65 mg kg -1 intraperitoneally (i.p.)) had little or no effect. However, mice receiving metformin (65 mg kg -1 i.p.) every other day for a total of 18 days, starting on day 10 post-bleomycin (1.25 U, i.t., intratracheal instillation) lung injury ( Supplementary Fig. 4a ), demonstrated significant reductions in several pro-fibrotic markers, including total lung hydroxyproline and the expression of α -SMA ( Supplementary Fig. 4b-d ). Histology and immunohistochemistry show diminished amounts of collagen and α -SMA ( Supplementary  Fig. 4e ). Importantly, these effects of metformin are abrogated in mice genetically deficient in the AMPKα 1 subunit ( Supplementary  Fig. 4d,f) . We also examined the effects of delayed metformin treatment (65 mg kg -1 , i.p.), that is, 3 weeks after bleomycin injury for up to an additional 5 weeks (Fig. 4a ). Metformin promotes fibrosis resolution even after delayed exposure ( Fig. 4b-d ). Notably, metformin stimulates TFAM and NADH ubiquinone dehydrogenase 1β subcomplex 8 (NDFUB8) expression in vivo, indicative of enhanced mitochondrial biogenesis, while α -SMA expression is reduced (Fig. 4e ). Lung tissue sections revealed a distinct pattern of AMPK activity in normal and fibrotic regions. During the reparative phase of lung injury, AMPK activity is primarily observed in relatively normal-appearing regions of the lung, while regions of active fibrotic remodelling with abundant α -SMA expression are deficient in AMPK activity (Fig. 4f,g and Supplementary Fig. 5a-c) , despite similar levels of the total amount of AMPK ( Supplementary Fig. 6 ). Reduced AMPK activation was confirmed in lung fibroblasts isolated from lungs of mice with established fibrosis ( Supplementary  Fig. 5d ). These results are concordant with the observation that AMPK activity is markedly diminished in areas of active fibrosis in individuals with IPF ( Fig. 1 and Supplementary Fig. 1) .
To our knowledge, this is the first study to demonstrate that the resolution of lung fibrosis can be accelerated with a pharmacological intervention that targets cellular metabolism. We provide mechanistic insights into myofibroblast deactivation that include enhanced collagen turnover via AMPK-dependent activation of autophagy, while mitochondrial biogenesis is associated with a restoration of sensitivity to intrinsic apoptosis. Although metformin may mediate multiple effects, the loss of its protective effect in AMPKα 1-deficient mice indicates that AMPK-autophagy and AMPK-dependent mitochondrial biogenesis are probable critical mechanisms of metformin action. Although we show that AMPK activation promotes myofibroblast deactivation/apoptosis, it is possible that AMPK activation in other cell populations, including alveolar epithelial cells and immune cells, may also mediate pro-resolution and/or anti-fibrotic effects 12, 13, 39 . Additional salutary effects of AMPK activation may involve clearance of apoptotic cells 40 , an important step in the resolution of both inflammation and fibrosis. Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism. Additionally, we provide proof of concept that activation of AMPK by metformin or other pharmacological agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.
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Methods Human lung tissues. The study protocol was approved by the local ethics committee under the University of Alabama at Birmingham Institutional Review Board. Lung sections of either healthy or IPF biopsies were provided by the Airway Tissue Procurement Program Facility at the University of Alabama, Birmingham, and the Pulmonary Hypertension Breakthrough Initiative. Lung sections were formalin-fixed and paraffin-embedded before being cut into 5 µ m slices, as previously described 41 .
Mice. All experiments were conducted in accordance with protocols approved by the University of Alabama at Birmingham Animal Care and Use Committee. Male mice (C57BL/6), 8 to 10 weeks of age were purchased from the Jackson Laboratory. The mice were kept on a 12 h light-dark cycle with free access to food and water. AMPKα1 −/− mice were provided by B. Viollet (Université Paris Descartes) and G. Shailendra (Henry Ford Health System).
Mouse model for bleomycin-induced lung injury and development of lung fibrosis.
For bleomycin administration, mice were anaesthetized with isoflurane followed by intratracheal instillation of bleomycin (1.25 U kg -1 , i.t.) in 60 µ l PBS, as previously described 42 . Mice received the first dose of saline (control group) or metformin (65 mg kg -1 , i.p.) 10 days after bleomycin, as described in the main text. Saline or metformin (65 mg kg -1 , i.p.) was then administered every second day for an additional 18 days. Further experiments were designed to measure the effects of delayed metformin administration. In particular, metformin treatment was initiated 3 weeks after exposure to bleomycin, and mice received metformin (every other day) for 5 weeks.
Reagents and antibodies.
Recombinant human TGF-β 1 was purchased from R&D systems. Metformin, RPMI 1640 and antimycin A were obtained from Sigma-Aldrich. AICAR was purchased from Toronto Research Chemicals. Bleomycin sulfate, specific siRNA to AMPKα 1/2 subunit, scrambled siRNA and Accell culture medium were purchased from Thermo Fisher Scientific. An In Situ Cell Death Detection Kit (TUNEL assay) was obtained from Roche. Antibodies to phospho-Thr172 AMPK and cl. PARP were purchased from Cell Signaling Technology. For immunohistochemistry, anti-phospho-Thr172 AMPK antibody was obtained from Cell Signaling Technology whereas total anti-total AMPKα subunit and anti-T1α IgG were purchased from R&D Systems. Antibodies to β -actin, fibronectin and α -SMA were obtained from Sigma-Aldrich, whereas anti-GAPDH antibody was from EMD Millipore. Anti-human collagen (type I) antibody was purchased from Abcam. Goat anti-rabbit and anti-mouse IgG with horseradish peroxidase (HRP) conjugate were obtained from Bio-Rad. Emulsion oil solution containing 4′ ,6-diamidino-2-phenylindole (DAPI) was from Vector Laboratories and Hoechst dye was from Life Technologies.
Hydroxyproline content of whole lung. Mouse lung tissues were homogenized using 100 µ l of water for every 10 mg of tissue. Next, 100 µ l HCl (12 N) were added per each 100 µ l sample of homogenate. Samples in Teflon-capped vials were hydrolysed at 96 °C for 48 h, then 10 µ l of each sample was transferred to a 96-well plate and evaporated under vacuum until dry. Chloramine T reagent (100 µ l) was added to each sample and incubated at room temperature for 5 min. p-Dimethylaminobenzaldehyde reagent (100 µ l) was added to each well and incubated for 90 min at 60 °C. Absorbance was measured (λ = 560 nm) using a BioTek ELx800 plate reader. The amount of hydroxyproline in samples was calculated using standard (rat tail collagen), prepared according to the manufacturer's protocol (BioVision).
Lung histology and imaging. Mouse lungs were inflated with 1 ml of 10% paraformaldehyde/PBS solution and embedded in paraffin. Sections (5-µ m-thick, mouse and human) were deparaffinized in serial solutions of Citrisolv (Fisher Scientific), isopropyl alcohol and water, followed by antigen retrieval by steaming in 10 mM citric acid (pH 6.0) for 20 min followed by a 20 min cooling period. The lung sections (mouse or human non-IPF or IPF) were washed with TBST buffer and blocked with 3% BSA for 90 min. Next, samples were incubated with anti-phospho-Thr172 AMPK, total AMPK, anti-α -SMA or anti-T1α antibody overnight at 4 °C and then secondary FITC or rhodamin-labelled antibody for 60 min. Nuclei were stained with DAPI. Fluorescent intensity was measured in randomly chosen area sections of control and IPF lung sections, or in sections obtained from experimental groups of mice. The levels of fluorescence were quantitated and displayed as two-dimensional scattergrams using HCImage Hamamatsu's image acquisition and analysis software. We also processed paraffinembedded tissue sections for lung histology and immunohistochemical staining, including H&E, Masson's trichrome or α -SMA staining, as previously described 42 .
Culture of fibroblast populations. Control (non-IPF) and IPF human lung fibroblasts were provided through the Clinical Core UAB. Human lung diploid (IMR90) fibroblasts were obtained from American Type Culture Collection (ATCC). Cells were cultured in RPMI 1640 medium and DMEM supplemented with 10% heat-inactivated FBS, penicillin (100 U ml -1 ), streptomycin (25 μ g ml -1 ) and l-glutamine (1 mM). Cells were maintained at 37 °C in a 5% CO 2 incubator.
Western blot analysis. Western blot analyses were performed as described previously 43 . Briefly, cell lysates or lung homogenates were prepared using lysis buffer containing Tris pH 7.4 (50 mM), NaCl (150 mM), NP-40 (0.5%, vol/vol), EDTA (1 mM), EGTA (1 mM), okadaic acid (1 nM) and protease inhibitors. The protein concentrations in the supernatants were determined using the Bradford reagent (Bio-Rad) with BSA as standard. After SDS-PAGE, PVDF membranes were probed with specific antibodies as described in the figure legends followed by detection with HRP-conjugated goat anti-rabbit or anti-mouse IgG. Bands were visualized by enhanced chemiluminescence (Super Signal, Pierce Biotechnology) and quantified with AlphaEaseFC software (Alpha Innotech).
Extracellular matrix extraction. Extracellular matrix extraction was performed on culture fibroblasts, as described previously 44 . siRNA knockdown of beclin, LC3B and AMPK. Fibroblasts were incubated with specific siRNA (0.1 μ M) to AMPKα 1/2, beclin or LC3B, as described previously 43 . Briefly, cells (2.5 × 10 4 per well) in 24-well plates were incubated in Accell medium (serum-free) containing specific or scrambled siRNA (0.1 μ M) for 72 h. After incubation with siRNA, the cell culture medium was changed to RPMI 1640 medium supplemented and treated as described in the figure legends. The sense sequences used for siRNA are as follows: beclin-1: CAGUUUGGCACAAUCAAUA; LC3B: GAAGGCGCUUACAGCUCAA and AMPKα : AUGAUGUCAGAUGGUGAAUUU; non-targeting: UAAGGCUAUGAAGAGAUAC.
Measurement of fibroblast bioenergetics. The bioenergetics was determined using an XF24 analyser from Seahorse Bioscience, which measures O 2 consumption and proton production (pH) in intact cells, as performed previously 45 . In particular, the OCR is correlated with oxidative phosphorylation, and proton production (extracellular acidification rate) can be related to glycolysis. Measurements were performed using 5 × 10 4 cells per well, plated on XF24 plates. The plate was then washed with XF assay buffer (DMEM, 5% FBS supplemented with 5.5 mM d-glucose, 4 mM l-glutamine and 1 mM pyruvate (pH 7.4)) and incubated in XF buffer for 30-60 min before the assay. All results were corrected for the cell number in individual wells.
Transmission electron microscopy. Lung fibroblasts were fixed in 2.5% glutaraldehyde in 0.05 M cacodylate buffer with 0.1 M NaCl, pH 7.5 for 20 min at room temperature, as previously described 46 . TEM images and quantitative analyses of morphometric data from the images were obtained in collaboration with the High Resolution Image Facility (UAB).
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding authors upon reasonable request.
